![](https://i-invdn-com.investing.com/news/LYNXMPEB2C0AG_L.jpg)
Earnings call: Geron reports promising start for RYTELO in MDS treatment
Geron (NASDAQ:GERN) Corporation (NASDAQ: GERN), a biopharmaceutical company, has reported encouraging early launch results for its new drug RYTELO, designed to treat lower-risk myelodysplastic syndromes (MDS). As of July 31, 2024, around 160 patients have …